🔥The 9th Round of Easy Loan, Earn $40 Reward is in progress❗️ ⏰ Promotion Period: January 15th - Feburary 15th, 2025 👉 Register now and check more details at gate.io/campaigns/358

Lung cancer support group happening now linkedin.com/posts/raja-mud…

I’d like to share this link from one of my patients who is in need of his immunotherapy treatment, but not been able to receive it due to high out of pocket deductible. It’s sad to see this in the US gofundme.com/f/my-cancer-im…

Our lung cancer support group will be this coming Tuesday, 11/17/2020 at 430 pm via zoom Those interested please contact me for link

Is this democracy AMERICAN??? Will someone say it like it is and put it out : TRUMP is responsible for this coup and he is trying to impose himself as president. Where’s the law???

I don’t know about other states, but in FL vaccine rollout has been shameful. HCP’s with no hospital affiliation not able to receive the vaccine. There is no path for them. Patients calling for hours to make appointments. Hospitals were put In charge but not serving the community

I'm raising money to Help Patient X cover her cancer medical expenses. Click to Donate gofund.me/142442c7

While I would love to post something academic, am unable to do it while watching Palestinians getting killed by the Israeli regime. Ok I said it. You may unfollow me now

#ASCO2022 Happy to be able to return to in-person meeting and catching up with colleagues… except for the lines at registration.

The reality of medical meetings during COVID times

I am very concerned that now in #Florida , the state allows HCP’s to refuse care based on personal beliefs!!! Discrimination and personal beliefs HAVE NO PLACE IN MEDICINE #stophate #wetookanoath #hippocraticoath

ASCO 2024 lots of new data coming out for lung cancer patients. ADC’s, cellular therapy and others

Subcutaneous Amivantamab should become the standard SC versus IV amivantamab PFS and OS better Infusion reactions 13 % vs 66% VTE 10 vs 21% #ASCO2024

Crown trial 5 yr update Lorlatinib vs. Crizotinib At 5-yrs, Median Os has not been reached yet. Although not compared to Alectinib, indirect comparison suggests the median OS is impressive with Lorlatinib. We should not being doing trials with Crizotinib please

🚀 Exciting KRAS breakthrough at #ASCO24! Researchers unveil promising new therapies targeting this notorious gene mutation in #LungCancer. 🌟 Hope is on the horizon for patients and families! 🧬💪 #CancerResearch #KRAS #Oncology #MedicalInnovation 🎉✨

Excellent presentation at the educational session on options for oncogene addicted NSCLC. A great review of all trials for EGFR at all stages. Neoadjuvant approach is exciting and awaiting trial results (ADAURA 2) #ASCO24 #lungcancer

The practice-changing data from the Laura trial demonstrated that adjuvant treatment with osimertinib significantly improved (DFS) compared to placebo early-stage EGFR-mutated NSCLC. statistically significant reduction in the risk of disease recurrence or death with osi #ASCO24